Belite Bio BLTE
NASDAQ BLTE
$155.94 -0.58 (-0.37%)
At close: Nov 11, 2026 · 4:00 PM EST

Belite Bio (BLTE) Preferred Stock Liabilities (2021)

Updated

Belite Bio's Preferred Stock Liabilities came in at $31.81 million for Q4 2021, unchanged from $31.81 million a year earlier.

Analysis

Belite Bio (BLTE) Preferred Stock Liabilities (2021) Analysis & Trends

  • Going back by year, Preferred Stock Liabilities was $31.81 million in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Belite Bio 6.16 Bn 6.16 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 31.81 Mn
API Access

Belite Bio Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=BLTE&period=max&api_key=YOUR_API_KEY